INVOKE: A phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors.

Authors: Neal Shiv Chawla, Luke Kuttschreuter, Kamlesh Kumar Sankhala, Sarah Benafif, Louise Carter, Nicholas Coupe, T.R. Jeffry Evans, Timothy Guy Humphries, Steven Chuan-Hao Kao, Harriet S. Walter, Andy Karabajakian, Alexandre Grimaldi, Caroline Hoffmann, Gill Low, Andrew Pierce, Stephane Champiat

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps2683

Source: Full article

---

Abstract

TPS2683